Journalartikel

Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases


AutorenlisteFurer, Victoria; Rondaan, Christien; Agmon-Levin, Nancy; van Assen, Sander; Bijl, Marc; Kapetanovic, Meliha Crnkic; de Thurah, Annette; Mueller-Ladner, Ulf; Paran, Daphna; Schreiber, Karen; Warnatz, Klaus; Wulffraat, Nico M.; Elkayam, Ori

Jahr der Veröffentlichung2021

ZeitschriftRMD Open: Rheumatic and Musculoskeletal Diseases

Bandnummer7

Heftnummer1

ISSN2056-5933

Open Access StatusGold

DOI Linkhttps://doi.org/10.1136/rmdopen-2021-001594

VerlagBMJ Publishing Group


Abstract
In view of the COVID-19 pandemic, there is an unmet clinical need for the guidelines on vaccination of patients with autoimmune inflammatory rheumatic diseases (AIIRD). This position paper summarises the current data on COVID-19 infection in patients with AIIRD and development of vaccines against COVID-19, discusses the aspects of efficacy and safety of vaccination, and proposes preliminary considerations on vaccination against COVID-19 in patients with AIIRD, mainly based on the expert opinion and knowledge on the use of other vaccines in this population of patients.



Zitierstile

Harvard-ZitierstilFurer, V., Rondaan, C., Agmon-Levin, N., van Assen, S., Bijl, M., Kapetanovic, M., et al. (2021) Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases, RMD Open: Rheumatic and Musculoskeletal Diseases, 7(1), Article e001594. https://doi.org/10.1136/rmdopen-2021-001594

APA-ZitierstilFurer, V., Rondaan, C., Agmon-Levin, N., van Assen, S., Bijl, M., Kapetanovic, M., de Thurah, A., Mueller-Ladner, U., Paran, D., Schreiber, K., Warnatz, K., Wulffraat, N., & Elkayam, O. (2021). Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open: Rheumatic and Musculoskeletal Diseases. 7(1), Article e001594. https://doi.org/10.1136/rmdopen-2021-001594



Schlagwörter


Autoimmune DiseasesCLINICAL-COURSEMETHOTREXATESYSTEMIC-LUPUS-ERYTHEMATOSUS


Nachhaltigkeitsbezüge


Zuletzt aktualisiert 2025-10-06 um 11:22